Tivona Capital | Rosetta Genomics

4733

portfolio_page-template-default,single,single-portfolio_page,postid-4733,ajax_fade,page_not_loaded,,wpb-js-composer js-comp-ver-4.1.2,vc_responsive

Rosetta Genomics

CATEGORY

Biotech

ABOUT

Rosetta Genomics is at the forefront of microRNA technology in the diagnosis and treatment of critical unmet needs in cancer and other disease areas. Rosetta was founded in 2000 and went public in 2007 (NASDAQ: ROSG).